Cyrus Biotechnology

Cyrus Biotechnology, founded in 2014, is a pre-clinical-stage biotech company based in Seattle, WA. With a focus on discovering novel biologics, the company leverages computational structure biology, AI, and massively parallel protein engineering. Through its innovative approach, Cyrus is dedicated to addressing serious unmet medical needs in various indications. The company collaborates with leading biotech and pharma companies and research institutes to advance its programs from discovery to the clinic. Cyrus Biotechnology is built on core software from the lab of David Baker at the University of Washington. The company has garnered support from influential investors, including OrbiMed, Trinity Ventures, Springrock, Agent Capital, iSelect, Yard Ventures, WRF, and Alexandria, making it a prominent player in the biotechnology and nutrition industries. Notably, Cyrus Biotechnology secured an $18.00M Series B investment on 06 December 2021, with support from Chestnut Street Ventures, Trinity Ventures, OrbiMed, Agent Capital, iSelect, W Fund, Selecta Biosciences, and the Washington Research Foundation. Cyrus Biotechnology's commitment to innovation, strong industry partnerships, and substantial financial backing positions it as a promising player in the biotech landscape. The company's dedication to leveraging advanced technology for the benefit of medical research and the development of groundbreaking biologics highlights its potential for impactful growth and success in addressing critical healthcare challenges. With a focus on expansion and talent acquisition, Cyrus Biotechnology presents an exciting opportunity for venture capital investors looking to support pioneering advancements in the biotechnology sector.